15.54  -0.46 (-2.88%)		02-13 16:00
Open: 16.125 High: 16.53 Volume: 898,857		Pre. Close: 16 Low: 15.505 Market Cap: 2,514(M)

Short term
Mid term
Targets	6-month :	20.91	1-year :	22.64
Resists	First :	17.9	Second :	19.38
Pivot price	17.41
Supports	First :	15.5	Second :	12.9
MAs	MA(5) :	16.46	MA(20) :	17.4
	MA(100) :	18.15	MA(250) :	14.1
MACD	MACD :	-0.6	Signal :	-0.5
%K %D	K(14,3) :	7.9	D(3) :	17.2
RSI	RSI(14): 34.2
52-week	High :	25	Low :	6.36

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ DYN ] has closed above bottom band by 0.8%. Bollinger Bands are 23.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	16.57 - 16.66	16.66 - 16.74
Low:	15.28 - 15.4	15.4 - 15.5
Close:	15.37 - 15.56	15.56 - 15.7

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Tue, 10 Feb 2026
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Unveiling A 130% Potential Upside - DirectorsTalk Interviews

Tue, 27 Jan 2026
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? - Nasdaq

Tue, 27 Jan 2026
Dyne Therapeutics: 2026 Catalysts Point To Further Upside (NASDAQ:DYN) - Seeking Alpha

Sat, 24 Jan 2026
Dyne Therapeutics (DYN) Is Up 7.8% After Japan Grants Orphan Status To DM1 Drug Candidate - Sahm

Thu, 15 Jan 2026
Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN) - Yahoo Finance

Tue, 13 Jan 2026
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - Investing News Network

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	165 (M)
Shares Float	134 (M)
Held by Insiders	0.4 (%)
Held by Institutions	109.6 (%)
Shares Short	18,890 (K)
Shares Short P.Month	14,950 (K)

EPS	-3.62
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.84
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-34.4 %
Return on Equity (ttm)	-60.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.72
Qtrly Earnings Growth	0 %
Operating Cash Flow	-376 (M)
Levered Free Cash Flow	-242 (M)

PE Ratio	-4.3
PEG Ratio	0
Price to Book value	3.2
Price to Sales	0
Price to Cash Flow	-6.82

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.